NervGen Pharma (NASDAQ:NGEN) Downgraded to Sell Rating by Wall Street Zen

NervGen Pharma (NASDAQ:NGEN) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Other equities analysts have also recently issued research reports about the company. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. Zacks Research upgraded NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. TD Cowen began coverage on NervGen Pharma in a report on Thursday, June 11th. They set a “buy” rating for the company. Stifel Nicolaus raised shares of NervGen Pharma to a “strong-buy” rating in a research note on Thursday, April 23rd. Finally, Weiss Ratings began coverage on shares of NervGen Pharma in a research report on Friday, April 24th. They set a “sell (d-)” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NervGen Pharma has an average rating of “Moderate Buy” and an average price target of $18.00.

NervGen Pharma Trading Up 1.1%

NGEN stock traded up $0.02 on Friday, hitting $1.88. The company’s stock had a trading volume of 785,706 shares, compared to its average volume of 480,269. The stock has a market capitalization of $151.59 million and a PE ratio of -20.89. The firm’s 50 day simple moving average is $2.48. NervGen Pharma has a 1 year low of $1.70 and a 1 year high of $6.30.

NervGen Pharma (NASDAQ:NGEN) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.